W Asher Wolf1, Cary C Cotton2, Daniel J Green2, Julia T Hughes2, John T Woosley3, Nicholas J Shaheen1, Evan S Dellon1. 1. Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, Chapel Hill, NC; Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC. 2. Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, Chapel Hill, NC. 3. Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.
Abstract
AIM: No consensus exists on the definition of successful treatment in eosinophilic esophagitis (EoE). The aim of this study was to identify the optimal histologic cutpoint to define successful treatment of EoE by assessing rates of symptomatic and endoscopic improvement. MATERIALS AND METHODS: We performed a retrospective cohort study utilizing the University of North Carolina EoE Clinicopathologic Database between 2006 and 2013. Rates of symptomatic and endoscopic improvement were determined, as were post-treatment eosinophil counts. The area under the receiver operator characteristic curve (AUC) was calculated for symptomatic and endoscopic response at several possible eosinophil count cutpoints (eos/hpf). Predictors of response were also assessed. RESULTS: Of 224 treatments in 199 patients, 76% were associated with symptomatic improvement, 68% with endoscopic improvement, and 60% with both. Of treatments that resulted in a post-treatment count of <15 eos/hpf, 90% were associated with an endoscopic response, 88% with a symptomatic response, and 81% with both symptomatic and endoscopic responses. Using a <15 eos/hpf threshold, the area under the curves (AUCs) were 0.70, 0.78, and 0.75 for symptomatic, endoscopic, and symptomatic/endoscopic responses, respectively. Lower histologic cut-points did not result in a substantial gain in response, but decreased the AUC. CONCLUSION: In this large cohort of EoE patients, rates of symptomatic and endoscopic improvement were generally associated with histologic improvement. A histologic cutoff for treatment response of <15 eos/hpf may balance clinical outcomes and test performance.
AIM: No consensus exists on the definition of successful treatment in eosinophilic esophagitis (EoE). The aim of this study was to identify the optimal histologic cutpoint to define successful treatment of EoE by assessing rates of symptomatic and endoscopic improvement. MATERIALS AND METHODS: We performed a retrospective cohort study utilizing the University of North Carolina EoE Clinicopathologic Database between 2006 and 2013. Rates of symptomatic and endoscopic improvement were determined, as were post-treatment eosinophil counts. The area under the receiver operator characteristic curve (AUC) was calculated for symptomatic and endoscopic response at several possible eosinophil count cutpoints (eos/hpf). Predictors of response were also assessed. RESULTS: Of 224 treatments in 199 patients, 76% were associated with symptomatic improvement, 68% with endoscopic improvement, and 60% with both. Of treatments that resulted in a post-treatment count of <15 eos/hpf, 90% were associated with an endoscopic response, 88% with a symptomatic response, and 81% with both symptomatic and endoscopic responses. Using a <15 eos/hpf threshold, the area under the curves (AUCs) were 0.70, 0.78, and 0.75 for symptomatic, endoscopic, and symptomatic/endoscopic responses, respectively. Lower histologic cut-points did not result in a substantial gain in response, but decreased the AUC. CONCLUSION: In this large cohort of EoE patients, rates of symptomatic and endoscopic improvement were generally associated with histologic improvement. A histologic cutoff for treatment response of <15 eos/hpf may balance clinical outcomes and test performance.
Authors: Charles W DeBrosse; James P Franciosi; Eileen C King; Bridget K Buckmeier Butz; Allison B Greenberg; Margaret H Collins; J Pablo Abonia; Amal Assa'ad; Philip E Putnam; Marc E Rothenberg Journal: J Allergy Clin Immunol Date: 2011-06-02 Impact factor: 10.793
Authors: Evan S Dellon; Xiaoxin Chen; C Ryan Miller; John T Woosley; Nicholas J Shaheen Journal: Am J Gastroenterol Date: 2012-07-10 Impact factor: 10.864
Authors: Chris A Liacouras; Glenn T Furuta; Ikuo Hirano; Dan Atkins; Stephen E Attwood; Peter A Bonis; A Wesley Burks; Mirna Chehade; Margaret H Collins; Evan S Dellon; Ranjan Dohil; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; David A Katzka; Alfredo J Lucendo; Jonathan E Markowitz; Richard J Noel; Robert D Odze; Philip E Putnam; Joel E Richter; Yvonne Romero; Eduardo Ruchelli; Hugh A Sampson; Alain Schoepfer; Nicholas J Shaheen; Scott H Sicherer; Stuart Spechler; Jonathan M Spergel; Alex Straumann; Barry K Wershil; Marc E Rothenberg; Seema S Aceves Journal: J Allergy Clin Immunol Date: 2011-04-07 Impact factor: 10.793
Authors: Scott Pentiuk; Phillip E Putnam; Margaret H Collins; Marc E Rothenberg Journal: J Pediatr Gastroenterol Nutr Date: 2009-02 Impact factor: 2.839
Authors: Glenn T Furuta; Chris A Liacouras; Margaret H Collins; Sandeep K Gupta; Chris Justinich; Phil E Putnam; Peter Bonis; Eric Hassall; Alex Straumann; Marc E Rothenberg Journal: Gastroenterology Date: 2007-08-08 Impact factor: 22.682
Authors: Alain M Schoepfer; Alex Straumann; Radoslaw Panczak; Michael Coslovsky; Claudia E Kuehni; Elisabeth Maurer; Nadine A Haas; Yvonne Romero; Ikuo Hirano; Jeffrey A Alexander; Nirmala Gonsalves; Glenn T Furuta; Evan S Dellon; John Leung; Margaret H Collins; Christian Bussmann; Peter Netzer; Sandeep K Gupta; Seema S Aceves; Mirna Chehade; Fouad J Moawad; Felicity T Enders; Kathleen J Yost; Tiffany H Taft; Emily Kern; Marcel Zwahlen; Ekaterina Safroneeva Journal: Gastroenterology Date: 2014-08-23 Impact factor: 22.682
Authors: Evan S Dellon; Ademola Aderoju; John T Woosley; Robert S Sandler; Nicholas J Shaheen Journal: Am J Gastroenterol Date: 2007-07-07 Impact factor: 10.864
Authors: Swathi Eluri; Sara R Selitsky; Irina Perjar; Johnathan Hollyfield; Renee Betancourt; Cara Randall; Spencer Rusin; John T Woosley; Nicholas J Shaheen; Evan S Dellon Journal: Clin Gastroenterol Hepatol Date: 2018-09-10 Impact factor: 11.382
Authors: E S Dellon; L L Higgins; R Beitia; S Rusin; J T Woosley; R Veerappan; S R Selitsky; J S Parker; R M Genta; R H Lash; R Aranda; R J Peach; M Grimm Journal: Aliment Pharmacol Ther Date: 2016-05-18 Impact factor: 8.171
Authors: Evan S Dellon; John T Woosley; Ashley Arrington; Sarah J McGee; Jacquelyn Covington; Susan E Moist; Jessica H Gebhart; Joseph A Galanko; John A Baron; Nicholas J Shaheen Journal: Clin Gastroenterol Hepatol Date: 2019-09-06 Impact factor: 11.382
Authors: Matthew A Rank; Rajiv N Sharaf; Glenn T Furuta; Seema S Aceves; Matthew Greenhawt; Jonathan M Spergel; Yngve T Falck-Ytter; Evan S Dellon Journal: Ann Allergy Asthma Immunol Date: 2020-05 Impact factor: 6.347